CN111298090A - External use medicine liquid for treating gastrointestinal motility disorder disease - Google Patents
External use medicine liquid for treating gastrointestinal motility disorder disease Download PDFInfo
- Publication number
- CN111298090A CN111298090A CN202010279062.6A CN202010279062A CN111298090A CN 111298090 A CN111298090 A CN 111298090A CN 202010279062 A CN202010279062 A CN 202010279062A CN 111298090 A CN111298090 A CN 111298090A
- Authority
- CN
- China
- Prior art keywords
- parts
- gastrointestinal motility
- liquid medicine
- rhizoma
- treating gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external liquid medicine for treating gastrointestinal motility disorder diseases, and relates to the technical field of traditional Chinese medicines. The method comprises the following manufacturing raw materials: radix Curcumae, rhizoma Cyperi processed with vinegar, flos Caryophylli, Coptidis rhizoma, fructus evodiae, pericarpium Citri Tangerinae, rhizoma Pinelliae Preparata, Inulae flos, cortex Magnolia officinalis, Arecae semen, and rhizoma Zingiberis recens. The invention is used for treating gastrointestinal motility disorder diseases, and has the advantages of simple and easy use, low cost and expense, obvious curative effect, little side effect and easy popularization.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an external liquid medicine for treating gastrointestinal motility disorders.
Background
Gastrointestinal motility disorder refers to a pathological process in which smooth muscle cell motility disorder of gastrointestinal tract is caused by various causes, and is commonly seen in gastrointestinal motility diseases such as gastroesophageal reflux disease (GERD), Functional Dyspepsia (FD), Irritable Bowel Syndrome (IBS), Slow Transit Constipation (STC), and other systemic diseases such as diabetic gastroparesis, acute severe pancreatitis, and postoperative inflammatory bowel paralysis. With the establishment of the gastrointestinal motility disorder-associated Disease (DGIM) Mangu standard, gastrointestinal motility disorder has become a focus and focus of digestive system disease research.
According to the traditional Chinese medicine, the gastrointestinal motility disorder diseases can be divided into liver and stomach stagnated heat syndrome, gallbladder heat invading stomach syndrome, middle-deficiency qi adverse-rising syndrome, qi stagnation and phlegm obstruction syndrome, blood stasis obstruction syndrome, liver stagnation and qi stagnation syndrome, liver stagnation and spleen deficiency syndrome, spleen deficiency phlegm-dampness syndrome, cold-heat complicated syndrome, spleen deficiency and dampness obstruction syndrome, liver stagnation and spleen deficiency syndrome, spleen and kidney yang deficiency syndrome, spleen and stomach damp-heat syndrome, liver stagnation and qi stagnation syndrome, intestinal dryness-heat syndrome, intestinal excess heat syndrome, intestinal qi stagnation syndrome, lung and spleen deficiency, spleen and kidney yang deficiency syndrome, body and blood deficiency syndrome and the like due to different pathological causes of the gastrointestinal motility disorder diseases, wherein the main symptoms of the gastrointestinal motility disorder diseases caused by gallbladder heat invading stomach syndrome are ① bitter taste and dry throat, ② heart burn, secondary symptoms are ② 2 abdominal distention and pain, ② 0 chest pain and backache, ② 1 acid regurgitation, ② gas, ⑤ and qi thirst, ⑥ is easy to be mixed with thirst, ⑦, yellow hunger, yellow tongue and yellow tongue fur is ①, and red, dry tongue is red, dry tongue and dry tongue, and dry tongue is treated with dry tongue, and dry tongue ② and dry tongue, dry tongue marked by dry tongue dryness, dry tongue and dry tongue.
At present, the cost for developing gastrointestinal motility promoting drugs is up to billions of dollars per year in developed countries, and drugs such as metoclopramide, domperidone, cisapride, mosapride, granisetron, tegaserod and itopride are applied to clinic successively, so that a lot of drugs are still in need of development. However, clinical application shows that the western medicines for promoting gastrointestinal motility have less than ideal curative effect, and also have central nervous system, circulatory system and other side effects. Therefore, the search for an effective treatment scheme for improving various gastrointestinal motility disorders has great social significance and economic value, and is a very urgent and arduous task in front of the majority of medical workers.
Disclosure of Invention
The invention aims to provide an external liquid medicine for treating gastrointestinal motility disorder diseases, which has the advantages of simplicity, convenience, easy use, low cost and expense, obvious curative effect, less side effect and easy popularization.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
the method comprises the following manufacturing raw materials:
radix Curcumae, rhizoma Cyperi processed with vinegar, flos Caryophylli, Coptidis rhizoma, fructus evodiae, pericarpium Citri Tangerinae, rhizoma Pinelliae Preparata, Inulae flos, cortex Magnolia officinalis, Arecae semen, and rhizoma Zingiberis recens.
In the above technical solution, a more specific technical solution is: the weight parts of the raw materials are as follows: 16 to 32 parts of curcuma aromatica, 13 to 26 parts of vinegar rhizoma cyperi, 6 to 12 parts of clove, 4 to 8 parts of coptis, 6 to 12 parts of evodia rutaecarpa, 12 to 24 parts of dried orange peel, 16 to 32 parts of rhizoma pinellinae praeparata, 10 to 20 parts of inula flower, 16 to 32 parts of magnolia officinalis, 16 to 32 parts of betel nut and 6 to 12 parts of ginger.
Further, 24 parts of radix curcumae, 20 parts of vinegar rhizoma cyperi, 10 parts of clove, 6 parts of coptis chinensis, 10 parts of fructus evodiae, 18 parts of pericarpium citri reticulatae, 24 parts of rhizoma pinellinae praeparata, 15 parts of inula flower, 24 parts of mangnolia officinalis, 24 parts of betel nut and 10 parts of ginger.
Further, the application acupuncture points of the external liquid medicine are Ganshu, Danshu, Pishu and Weishu.
Further, the specific application method of the external liquid medicine comprises the following steps:
the patient takes the prone position and fully exposes the treatment site, and the physician wraps the finger with cotton each time, applies the liquid medicine to the points Ganshu, Danshu, Weishu and Pishu on the two sides of the patient, and performs the operation of pointing and pressing the abdomen of the thumb on each point for 1 minute first and then kneading for 1 minute from left to right and from top to bottom for 2 minutes.
Furthermore, the operating frequency of the point pressing is 120 times/minute to 160 times/minute, and the strength is based on the tolerance of the patient.
In the invention, the curcuma aromatica is dry root tuber of curcuma aromatica, curcuma longa, curcuma kwangxi or curcuma zedoaria of zingiberaceae, which is called as curcuma aromatica and curcuma kwangsiensis respectively.
The vinegar aroma is dried rhizome of Cyperus rotundus L.of Cyperaceae, also called herba Rabdosiae Glaucocalycis and fructus Rhododendri mollis, and is a name of traditional Chinese medicine.
The flos Caryophylli is flos Caryophylli of genus Caryophylli of Oleaceae, named as flos Caryophylli (flower bud), fructus Caryophylli (fruit), flos Caryophylli, JIUJIEXIANG, Male flos Caryophylli, and flos Caryophylli.
The Coptidis rhizoma is perennial herb of Coptidis rhizoma of Ranunculaceae, and is named separately as herba Coptidis, rhizoma Coptidis, and rhizoma Coptidis.
The fructus evodiae is fructus evodiae species of Evodia of Rutaceae, and is called fructus evodiae, tea pepper, fructus Capsici, fructus Ananadis Comosi, fructus Cichorii, and fructus Capsici.
The pericarpium Citri Tangerinae is pericarp of mature fruit of Rutaceae plant fructus Citri Tangerinae and its cultivar, and is called pericarpium Citri Tangerinae.
The rhizoma Pinelliae Preparata is tuber of rhizoma Pinelliae of Araceae, and is called rhizoma Pinelliae Preparata, and rhizoma Pinelliae Preparada.
The Inulae flos is perennial herb of Inulae flos of Compositae, named as flos Inulae, herba Inulae, and flos Laurenciae Angustifoliae.
The cortex Magnolia officinalis is dry bark, root bark and branch bark of Magnoliaceae and Magnoliaceae plants, and is called cortex Magnolia officinalis or Magnolia officinalis with purple oil.
The Arecae semen is evergreen tree of Arecae of Palmae, and is named as Arecae semen, Bingmen, Arecae semen, and fructus Canarii albi.
The rhizoma Zingiberis recens is fresh rhizome of Zingiber officinale Roscoe of Zingiberaceae, named as ginger peel, ginger root, and Baicaoyun.
Due to the adoption of the technical scheme, the invention has the beneficial effects that:
1. the invention is used for treating gastrointestinal motility disorder diseases, and has the advantages of simple and easy use, low cost and expense, obvious curative effect, little side effect and easy popularization.
2. In the formula, the turmeric root tuber and the nutgrass galingale rhizome have the effects of activating qi, smoothing qi movement and relieving pain; clove, being pungent and warm and aromatic, is good at warming middle energizer to dispel cold and strengthen yang; coptis root, rhizoma Coptidis, bitter in taste and cold in nature, can eliminate dampness and clear heat, and cold in nature can clear heat and purge fire; evodia rutaecarpa, fructus evodiae, with pungent and bitter taste, is hot and dry and drastic to dispel cold and alleviate pain, enters spleen, stomach and kidney channels, and can warm spleen and tonify kidney, warm middle-jiao and invigorate yang; pericarpium Citri Tangerinae and rhizoma Pinelliae Preparata for eliminating dampness and phlegm; inula flower, flos Inulae, pungent in flavor and bitter in flavor, has the effects of lowering the temperature and dredging the meridians of lung and stomach, and is good at lowering qi and eliminating phlegm, and combined with ban Xia and Sheng Jiang to resolve phlegm and harmonize the middle; magnolia officinalis, pungent and bitter with the action of dispersing and drying, warm in nature, excels in eliminating dampness, promoting qi circulation and eliminating phlegm; areca catechu promotes the circulation of qi, and ginger warms the middle-jiao and invigorates the spleen; the medicines are combined to play the roles of promoting qi circulation, relieving pain, dredging the abdomen and purging heat, peripheral nerves are stimulated through the action of manipulation, the center strengthens the function of the nerve endings through reflection to regulate gastrointestinal movement, further the peristalsis function of the stomach is recovered, the gastrointestinal motility is improved, and the dyspepsia symptoms are reduced.
3. The invention selects Ganshu, Danshu, Pishu and Weishu as the acupuncture points for drug application, and the back shu acupuncture points and the internal organs are mutually linked to achieve the purposes of regulating liver qi, regulating spleen and stomach and dredging middle energizer, promote the ascending and descending of the spleen and stomach to be orderly, restore the transportation and transformation functions to normal, improve various diseases and relieve the state of illness.
4. In the application process of the invention, the selection of 'from left to right and from top to bottom' is based on the traditional Chinese medicine theory that the left part is positive relative to the right part and the upper part is positive relative to the lower part, so as to achieve the purposes of adjusting the balance of yin and yang and communicating the interior and the exterior of viscera so as to regulate the gastrointestinal motility.
5. In the application process of the invention, the operation frequency of point pressing is selected to be 120-160 times/min, adverse reactions caused by different tolerance degrees can be reduced, channels and collaterals can be dredged, qi and blood can be regulated, the conduction of channel qi of channels and collaterals and acupoints of the body can be stimulated, and the recovery of the functions of the spleen and the stomach can be promoted.
Detailed Description
The invention is further described in detail below with reference to specific examples:
example 1 topical liquid medicine for the treatment of gastrointestinal motility disorders
The method comprises the following manufacturing raw materials:
24g of radix curcumae, 20g of vinegar-processed rhizoma cyperi, 10g of clove, 6g of coptis chinensis, 10g of fructus evodiae, 18g of dried orange peel, 24g of rhizoma pinellinae praeparata, 15g of inula flower, 24g of mangnolia officinalis, 24g of betel nut and 10g of ginger;
the preparation method comprises the following steps:
the raw material medicines are bottled in brown, 1L of 50-degree white spirit is added, and liquid medicine is taken for standby after soaking for 48 hours.
The specific application method comprises the following steps:
the patient takes the prone position, fully exposes the treatment part, wraps the finger with a proper amount of cotton each time, dips a little liquid medicine to coat the points of Ganshu, Danshu, Weishu and Pishu on the bladder of the foot of the patient, points the abdomen of the thumb on each point for 1 minute from left to right and from top to bottom, and then performs the operation of kneading for 1 minute, the operation frequency is 120 times/minute to 160 times/minute, and the force is based on the tolerance of the patient.
Example 2 topical liquid medicine for the treatment of gastrointestinal motility disorders
The method comprises the following manufacturing raw materials:
16g of radix curcumae, 26g of vinegar-processed rhizoma cyperi, 12g of clove, 4g of coptis chinensis, 6g of fructus evodiae, 24g of dried orange peel, 32g of rhizoma pinellinae praeparata, 10g of inula flower, 16g of mangnolia officinalis, 32g of areca nut and 6g of ginger;
the preparation method comprises the following steps:
the raw material medicines are bottled in brown, 1L of 50-degree white spirit is added, and liquid medicine is taken for standby after soaking for 48 hours.
The specific application method comprises the following steps:
the patient takes the prone position, fully exposes the treatment part, wraps the finger with a proper amount of cotton each time, dips a little liquid medicine to coat the points of Ganshu, Danshu, Weishu and Pishu on the bladder of the foot of the patient, points the abdomen of the thumb on each point for 1 minute from left to right and from top to bottom, and then performs the operation of kneading for 1 minute, the operation frequency is 120 times/minute to 160 times/minute, and the force is based on the tolerance of the patient.
EXAMPLE 3 topical liquid medicine for the treatment of gastrointestinal motility disorders
The method comprises the following manufacturing raw materials:
32g of radix curcumae, 13g of vinegar-processed rhizoma cyperi, 6g of clove, 8g of coptis chinensis, 12g of fructus evodiae, 12g of dried orange peel, 16g of rhizoma pinellinae praeparata, 20g of inula flower, 32g of mangnolia officinalis, 16g of betel nut and 12g of ginger;
the preparation method comprises the following steps:
the raw material medicines are bottled in brown, 1L of 50-degree white spirit is added, and liquid medicine is taken for standby after soaking for 48 hours.
The specific application method comprises the following steps:
the patient takes the prone position, fully exposes the treatment part, wraps the finger with a proper amount of cotton each time, dips a little liquid medicine to coat the points of Ganshu, Danshu, Weishu and Pishu on the bladder of the foot of the patient, points the abdomen of the thumb on each point for 1 minute from left to right and from top to bottom, and then performs the operation of kneading for 1 minute, the operation frequency is 120 times/minute to 160 times/minute, and the force is based on the tolerance of the patient.
Effect test section 1
1 determination of the test subjects: the representative disease of the digestive tract dyskinetic disorder, namely the gastroesophageal reflux disease, is taken as a test object, 90 cases of outpatients of traditional Chinese medicine clinics and hospitalized patients with gallbladder heat invading stomach syndrome type gastroesophageal reflux in Liuzhou city which meet the inclusion and exclusion standards are selected, the random codes of the computers are adopted for grouping, the reasonable distribution and hiding are adopted, namely the random codes of the computers are filled into a sealed envelope, the patients are randomly extracted, and the codes are sealed by a designer. The 90 patients were randomly divided into 30 treatment groups (hereinafter referred to as treatment groups) of the external liquid medicine for treating gastrointestinal motility disorders, 30 traditional Chinese medicine control groups and 30 western medicine control groups.
The traditional Chinese medicine syndrome type diagnostic standard of patients with biliary heat invading stomach syndrome type gastroesophageal reflux disease is as follows:
the main symptoms are ① bitter taste in mouth and dry throat and ② heartburn.
The secondary symptoms are ① abdominal pain, ② chest pain and backache, ③ acid regurgitation, ④ belching and regurgitation, ⑤ vexation and insomnia, ⑥ gastric upset and hunger, ⑦ red tongue with yellow and greasy fur and wiry and smooth pulse.
Inclusion criteria were as follows:
① meet the above diagnostic criteria and the diagnosis is accurate.
② age 18-60 years.
③ Western medicines for inhibiting acid and affecting gastrointestinal motility are not taken for at least 1 week.
④ normal consciousness, can be used in conjunction with clinical data collection.
⑤ patients gave informed consent to voluntary participation in the trial.
Exclusion criteria were as follows:
① patients with cardia or gastrectomy, combined Barrett esophagus, cardia achalasia, pyloric obstruction, peptic ulcer, digestive system tumor, hiatal hernia, and Zollinger-Ellison syndrome.
③ it is used for treating severe primary diseases of heart, cerebral vessels, liver, kidney, hemopoiesis, and endocrine system.
④ patients with neurological, psychiatric and infectious diseases.
⑤ pregnant, perinatal, and lactation women.
2, treatment in groups:
2.1 treatment group: back transport point therapy (selecting Ganshu, Danshu, Pishu, Weishu, etc. acupoints).
The operation process comprises the following steps:
① the doctor asks the patient for details and evaluates the patient's condition before treatment to get a good indication.
② the four diagnostic methods are combined and examined to make a prescription of acupoints.
③ the doctor clarifies the purpose and course of treatment to the patient in hope of coordination.
④ the back transport index therapy uses a medicinal liquid for external use for treating gastrointestinal motility disorders.
⑤ the method comprises applying the topical liquid medicine to the acupoints of FENGTAINGQIAOSHU, DANSHU, WEISHU and PISHU of patients, and performing the above-mentioned operations sequentially from left to right and from top to bottom, with the thumb and the abdomen on each acupoint for 1 min at the frequency of 120 times/min to 160 times/min and with the strength of the patient's tolerance.
The course of treatment is as follows: the preparation is administered 1 time daily, and 3 weeks is a course of treatment.
Operation considerations:
① those who are extremely nervous or extremely weak cannot tolerate the disease.
② those with hunger and satiety or drunkenness.
③ dermatoses, damaged skin, and tumor local parts.
④ it is forbidden for patients with severe visceral diseases and severe mental diseases.
⑤ the medical practitioner should cut short nails to avoid injury to the skin.
2.2 Chinese medicine control group
Therapeutic method: clearing away gallbladder heat, directing qi downward and harmonizing stomach
Selecting the following components: modified Longdan Xiegan Tang (Gentiana scabra Bunge decoction for purging liver fire) and Wendan Tang (Gentiana scabra Bunge decoction for warming gallbladder), the specific formula is as follows:
15g of gentian, 12g of radix bupleuri, 15g of (charred) gardenia, 9g of scutellaria baicalensis, 20g of angelica sinensis, 12g of inula flower, 9g of ochre, 10g of rhizoma pinellinae praeparata, 15g of bamboo shavings, 12g of fructus aurantii, 15g of dried orange peel and 15g of honey-fried licorice root.
The use method comprises the following steps: decocting with water to 400ml, and orally administering in the morning and evening.
2.3 Western medicine control group
The western medicine control group is administered 5mg of mosapride citrate dispersible tablet (Chengdu Kanghong pharmaceutical industry group GmbH 20031110) for oral administration 3 times per day; and combining Lansoprazole enteric-coated tablet (Shantou economic bougie Bine pharmaceutical factory, national drug Standard H10980136) 15mg, orally taking 2 times daily. 3 weeks is taken as 1 course of treatment.
3, treatment effect:
3.1 evaluation criteria for symptom efficacy
According to the 2009 traditional Chinese medicine diagnosis and treatment consensus opinion of gastroesophageal reflux disease, the disease is divided into 4 grades (0, I, II and III) according to the weight of symptoms, and the integral is divided into 0, 1, 2 and 3. The recording and evaluation of each individual symptom (acid regurgitation, heartburn, pain or discomfort after sternum, belching and regurgitation and other typical reflux symptoms) are mainly carried out. The effect is shown: the original symptoms disappear; the method has the following advantages: grade 2 improvement of the original symptoms; and (4) invalidation: the original symptoms are not improved or the original symptoms are aggravated.
3.2 the curative effect:
specific therapeutic effects are shown in table 1 below.
TABLE 1
Effect test part (ii):
1 determination of the test subjects: the following representative disease of digestive tract dyskinetic disorder, namely, the constipation with outlet obstruction, is taken as a test object, 90 cases of outpatients of traditional Chinese medicine clinics and patients with constipation with outlet obstruction with intestinal excess heat syndrome in hospital in Liuzhou city which meet the inclusion and exclusion standards are selected, the random codes of the computers are grouped and reasonably distributed and hidden, namely, the random codes of the computers are filled into a sealed envelope to allow the patients to randomly draw, and the codes are sealed by designers. The 90 patients were randomly divided into 30 treatment groups (hereinafter referred to as treatment groups) of "moxibustion sticks for treating gastrointestinal motility disorders" of the invention, 30 control groups of traditional Chinese medicines, and 30 control groups of western medicines.
Wherein, the traditional Chinese medicine syndrome diagnosis standard of the intestinal excess heat syndrome type outlet obstruction type constipation patient is as follows:
① constipation, ② abdominal pain and distending pain, and ③ bitter taste and halitosis.
The secondary symptoms comprise ① flushed face and fever, ② dysphoria and thirst, ③ scanty and brownish urine, ④ red tongue with yellow and dry coating, and smooth and solid pulse.
Inclusion criteria were as follows:
① meet the above diagnostic criteria, the diagnosis is definite;
② age 18-60 years;
③ Western medicine for inhibiting acid and affecting gastrointestinal motility is not taken for at least 1 week;
④ conscious, and can be used in conjunction with clinical data collection;
⑤ patients gave informed consent to voluntary participation in the trial.
Exclusion criteria were as follows:
① do not meet the inclusion criteria.
② has organic pathological changes of digestive tract, such as intestinal obstruction.
③ it is used for treating severe primary diseases of heart, cerebral vessels, liver, kidney, hemopoiesis, and endocrine system.
④ patients with neurological, psychiatric and infectious diseases.
⑤ pregnant, perinatal, and lactation women.
⑥ it can be used for treating constipation by long-term administration of drugs, such as sedative analgesic.
2, treatment in groups:
2.1 treatment group: back transport point therapy (selecting acupoints of Shu-Ganshu, Danshu, Pishu, Weishu, and Geshu).
The operation process comprises the following steps:
① the doctor asks the patient for details and evaluates the patient's condition before treatment to get a good indication.
② the four diagnostic methods are combined and examined to make a prescription of acupoints.
③ the doctor clarifies the purpose and course of treatment to the patient in hope of coordination.
④ the back transport index therapy uses a medicinal liquid for external use for treating gastrointestinal motility disorders.
⑤ the detailed operation method comprises fully exposing the treatment area, wrapping the finger with a proper amount of cotton each time, applying the topical liquid medicine for treating gastrointestinal dyskinetic diseases on the points Ganshu, Danshu, Pishu, Weishu and Geshu of foot-Taiyang bladder of the patient, and performing the above-mentioned operations sequentially from left to right and from top to bottom, with the thumb and the abdomen on each point, by first applying a point for 1 minute and then performing an Rou for 1 minute, with an operation frequency of 120-160 times/minute and a force corresponding to the tolerance of the patient.
The course of treatment is as follows: the preparation is administered 1 time daily, and 3 weeks is a course of treatment.
Operation considerations:
① those who are extremely nervous or extremely weak cannot tolerate the disease.
② those with hunger and satiety or drunkenness.
③ dermatoses, damaged skin, and local tumor, it is contraindicated in ④ women at lumbosacral region during menstrual period, pregnant woman abdomen, Hegu, Sanyinjiao, etc.
⑤ it is forbidden for patients with severe visceral diseases and severe mental diseases.
⑥ the operator should cut short the nails to avoid injury to the skin.
2.2 Chinese medicine control group
Therapeutic method: clear heat and moisten intestines.
Selecting the following components: modified Maziren Wan (fructus Cannabis pill), the specific formula is as follows:
15g of fructus cannabis, 20g of peony, 9g of almond, 10g of rhubarb, 15g of magnolia officinalis, 10g of immature bitter orange and 15g of edestan.
The use method comprises the following steps: decocting with water to 400ml, and orally administering 2 times daily, once in the morning and evening.
2.3 Western medicine control group
The preparation method is formulated according to a treatment scheme of the gastrointestinal motility group of China medical society for digestive diseases, namely '2013 Chinese diagnosis and treatment guidelines for chronic constipation': polyethylene glycol 1 bag Bid (Hunan Huana big pharmaceutical factory, Limited, national drug standards: H20052078) + succinic acid Purparib 2mg Qd (Xian Yang Sen pharmaceutical company, national drug standards: H20120564). 3 weeks is taken as 1 course of treatment.
3, treatment effect:
3.1 evaluation criteria for symptom efficacy
① the constipation standard is evaluated on the basis of constipation curative effect by referring to 2012 edition of Chinese medicine clinical disease diagnosis curative effect standard issued by the State administration of traditional Chinese medicine, namely, the constipation standard is divided into 4 standards of recovery, effect, effectiveness and ineffectiveness, the recovery is that the excrement is normal, other symptoms disappear when the defecation condition before illness (curative effect score is 0 and is kept for more than one month), the obvious effect is that the defecation difficulty is obviously improved, the defecation interval time is obviously shortened and the excrement softness is close to normal, or the defecation is carried out at least once within 2 days (curative effect score is 30 percent and is kept for more than one month), the effect is that the defecation interval time is shortened by 1 day, or the excrement hardness degree is improved, the curative effect score is 50 percent and is kept for more than one month), and the other symptoms disappear;
② the evaluation standard of the effective rate of the main comprehensive symptoms comprises the percentage of symptom improvement = (total integral before treatment-total integral after treatment)/total integral before treatment x 100%, the symptom disappears, the effective rate is more than or equal to 80%, the ineffective rate is less than 50%, and the total effective rate is calculated according to the sum of the number of the cases of the symptom improvement and the effective rate.
3.2 the curative effect:
the specific therapeutic effects are shown in Table 2 below.
TABLE 2
From the clinical test and data results, the external liquid medicine for treating gastrointestinal motility disorder diseases can effectively treat the gastrointestinal motility disorder diseases, particularly for the gastrointestinal motility disorder diseases with the syndrome of gallbladder heat invading the stomach and the constipation with the syndrome of intestinal excess heat type outlet obstruction.
Claims (6)
1. A liquid medicine for external use for treating gastrointestinal motility disorder diseases is characterized by comprising the following preparation raw materials:
radix Curcumae, rhizoma Cyperi processed with vinegar, flos Caryophylli, Coptidis rhizoma, fructus evodiae, pericarpium Citri Tangerinae, rhizoma Pinelliae Preparata, Inulae flos, cortex Magnolia officinalis, Arecae semen, and rhizoma Zingiberis recens.
2. The external liquid medicine for treating gastrointestinal motility disorders according to claim 1, which is characterized in that the raw materials are in parts by weight as follows: 16 to 32 parts of curcuma aromatica, 13 to 26 parts of vinegar rhizoma cyperi, 6 to 12 parts of clove, 4 to 8 parts of coptis, 6 to 12 parts of evodia rutaecarpa, 12 to 24 parts of dried orange peel, 16 to 32 parts of rhizoma pinellinae praeparata, 10 to 20 parts of inula flower, 16 to 32 parts of magnolia officinalis, 16 to 32 parts of betel nut and 6 to 12 parts of ginger.
3. The external liquid medicine for treating gastrointestinal motility disorders according to claim 2, wherein: 24 parts of radix curcumae, 20 parts of vinegar-processed rhizoma cyperi, 10 parts of clove, 6 parts of coptis chinensis, 10 parts of fructus evodiae, 18 parts of pericarpium citri reticulatae, 24 parts of rhizoma pinellinae praeparata, 15 parts of inula flower, 24 parts of mangnolia officinalis, 24 parts of betel nut and 10 parts of ginger.
4. A liquid medicine for external use for treating a gastrointestinal motility disorder according to claim 1, 2 or 3, wherein: the application acupuncture points of the external liquid medicine are Ganshu, Danshu, Pishu and Weishu.
5. The external liquid medicine for treating gastrointestinal motility disorders according to claim 4, wherein the specific administration method of the external liquid medicine is as follows:
the patient takes the prone position, fully exposes the treatment part, wraps the fingers with cotton each time, dips the external liquid medicine to coat the points of the bladder channel Ganshu, Danshu, Weishu and Pishu on the two sides of the patient, points the abdomen of the thumb on each point for 1 minute from left to right and from top to bottom, and then performs the operation for 2 minutes by kneading for 1 minute.
6. The topical liquid medicine for treating gastrointestinal motility disorders according to claim 5, wherein: the operating frequency of the point pressing is 120 times/minute to 160 times/minute, and the strength is the tolerance of the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010279062.6A CN111298090A (en) | 2020-04-10 | 2020-04-10 | External use medicine liquid for treating gastrointestinal motility disorder disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010279062.6A CN111298090A (en) | 2020-04-10 | 2020-04-10 | External use medicine liquid for treating gastrointestinal motility disorder disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111298090A true CN111298090A (en) | 2020-06-19 |
Family
ID=71162641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010279062.6A Withdrawn CN111298090A (en) | 2020-04-10 | 2020-04-10 | External use medicine liquid for treating gastrointestinal motility disorder disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111298090A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023002A (en) * | 2020-09-30 | 2020-12-04 | 深圳市三灸堂生物科技有限公司 | Moxibustion powder and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1127656A (en) * | 1995-09-03 | 1996-07-31 | 吴肇基 | Kinetogenesis Chinese medicine for gastrointestinal tract |
| CN102397372A (en) * | 2011-11-17 | 2012-04-04 | 云南云药科技股份有限公司 | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome |
| CN102743738A (en) * | 2012-07-27 | 2012-10-24 | 赵晓霞 | External use navel spreading sparadrap for treating gastrointestinal dysfunction |
| CN109316540A (en) * | 2017-07-31 | 2019-02-12 | 吴冰 | A kind of strengthening the spleen and stomach acupoint plaster and preparation method thereof |
-
2020
- 2020-04-10 CN CN202010279062.6A patent/CN111298090A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1127656A (en) * | 1995-09-03 | 1996-07-31 | 吴肇基 | Kinetogenesis Chinese medicine for gastrointestinal tract |
| CN102397372A (en) * | 2011-11-17 | 2012-04-04 | 云南云药科技股份有限公司 | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome |
| CN102743738A (en) * | 2012-07-27 | 2012-10-24 | 赵晓霞 | External use navel spreading sparadrap for treating gastrointestinal dysfunction |
| CN109316540A (en) * | 2017-07-31 | 2019-02-12 | 吴冰 | A kind of strengthening the spleen and stomach acupoint plaster and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 谢胜，等: "药穴指针疗法治疗胃食管反流病的疗效观察", 《中国中西医结合杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023002A (en) * | 2020-09-30 | 2020-12-04 | 深圳市三灸堂生物科技有限公司 | Moxibustion powder and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041317B (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN101181568B (en) | Traditional chinese medicine preparation for curing osteoproliferation as well as arthrosis ache | |
| CN102274479B (en) | Traditional Chinese medicine composition for treating functional dyspepsia | |
| CN111298090A (en) | External use medicine liquid for treating gastrointestinal motility disorder disease | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN102327512A (en) | Traditional Chinese medicine formula for treating prostatitis | |
| CN103223024B (en) | Diabetes mellitus dialectical traditional Chinese medicine prescription | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN101596270A (en) | A kind of medicine that is used for the treatment of chronic pharyngitis and preparation method thereof | |
| CN104888178A (en) | Infantile diarrhea treatment traditional Chinese medicine | |
| CN103330867A (en) | Preparation method of powder for treating senile vaginitis | |
| CN103623335B (en) | A kind of Chinese medicine preparation for the treatment of rhinitis | |
| CN106267127A (en) | A kind of Chinese medicine composition treating lumbago and skelalgia arthromyodynia and heat steam health promoting insoles | |
| CN102872293A (en) | Traditional Chinese medicinal powder for treating rheumatism and rheumatoid disease | |
| CN106344838A (en) | Chinese medicinal composition for treating oral ulcer | |
| CN105749243A (en) | Traditional Chinese medicine for treating coolness diseases | |
| CN105796951A (en) | External-use preparation used by radiology department for treating nasal polyp and preparation method | |
| CN105617162A (en) | Traditional Chinese medicine composition for treating aphthae | |
| CN104758889A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN116350729A (en) | Traditional Chinese medicine composition for treating epigastric pain and preparation method and application thereof | |
| CN104689086A (en) | Compound traditional Chinese medicine granule for treating oral ulcer and preparation method thereof | |
| CN104173857A (en) | Traditional Chinese medicine for treating yin-yang-deficiency diabetes mellitus II and preparation method of traditional Chinese medicine | |
| CN103157032B (en) | Postoperative medicine for chondroblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200619 |